LPTX

Leap Therapeutics, Inc. (LPTX) Reports Q1 Loss, Lags Revenue Estimates

Leap Therapeutics Reports First Quarter 2021 Financial Results

Leap Therapeutics and Flagship Biosciences Develop Image Analysis RNAscope Assay for Prospective Trial Enrollment

LPTX Stock: Over 2.5% Increase Pre-Market Explanation

Leap Therapeutics Announces Completion of Enrollment for First-Line Patient Cohort in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

LPTX Stock Price Increases Over 25% Pre-Market: Why It Happened